Oritavancin Diphosphate — Active Pharmaceutical Ingredient

Oritavancin Diphosphate is an active pharmaceutical ingredient found in 2 FDA-approved drug products. Forms: POWDER. Routes: INTRAVENOUS.

Drug Ingredients A–Z 1 min read
This content is for informational purposes only. Always consult a healthcare professional.

Oritavancin Diphosphate (2 brand names, 1 dosage form, 1 route)

Available dosage forms: POWDER.

Routes of administration: INTRAVENOUS.

Brand Names

  • KIMYRSA
  • ORBACTIV

Adverse Reactions

The following adverse reactions are also discussed in the Warnings and Precautions section of labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.2)] Infusion Related Reactions [see Warnings and Precautions (5.3)] Clostridioides difficile-Associated Diarrhea [see Warnings and Precautions (5.4)] Osteomyelitis [see Warnings and Precautions (5.6)]

Mechanism of Action

Oritavancin is an antibacterial drug [see Microbiology (12.4)].

Overdosage

Based on an in vitro hemodialysis study, KIMYRSA is unlikely to be removed from blood by hemodialysis. In the event of overdose, supportive measures should be taken.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.